Skip to Main Content

Author Details

Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
2006
79
34
PMIDPaper TitleJournal TitlePublished Year
36264026Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.Br J Haematol2023
37698624Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood Cancer Discov2023
37199721Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases.Clin Cancer Res2023
33375770Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.Haematologica2022
36536477Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.Clin Transl Med2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36307214Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.Cold Spring Harb Mol Case Stud2022
35078224Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.Blood Adv2022
33403501NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.Invest New Drugs2021
33712704Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.Oncogene2021
34301758Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations.Cancer Res2021
34233449Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia.Haematologica2021
32366937ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.Leukemia2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
32296029NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2[V617F]-positive myeloproliferative neoplasm cells.Signal Transduct Target Ther2020
32289275Response and Resistance to BCR-ABL1-Targeted Therapies.Cancer Cell2020
30651561Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.Nat Commun2019
31754026Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.Proc Natl Acad Sci U S A2019
31543464Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.Cancer Cell2019
31311809Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.Cancer Res2019
31366621Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.Blood2019
29284681A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemia.Haematologica2018
30082821Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Leukemia2018
30018082Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.Sci Signal2018
29872489Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.Oncotarget2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
29472557Metformin exerts multitarget antileukemia activity in JAK2<sup>V617F</sup>-positive myeloproliferative neoplasms.Cell Death Dis2018
28630439Recurrent cyclin D2 mutations in myeloid neoplasms.Leukemia2017
28409891Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.Pediatr Blood Cancer2017
28355571Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.Cell Rep2017
28186983Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.Oncotarget2017
29078326CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.Proc Natl Acad Sci U S A2017
28784769Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Proc Natl Acad Sci U S A2017
28586338Understanding cancer from the stem cells up.Nat Med2017
26755644IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.Oncotarget2016
26673800A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.Clin Cancer Res2016
26475333The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.Clin Cancer Res2016
26582647Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.Leukemia2016
27582059Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.Sci Transl Med2016
27235757Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.Exp Hematol2016
25109334Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Oncogene2015
26625308Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Oncotarget2015
26372962Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Proc Natl Acad Sci U S A2015
26032424Therapeutically Targetable ALK Mutations in Leukemia.Cancer Res2015
25700679Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Curr Hematol Malig Rep2015
24436473Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Clin Cancer Res2014
25293778BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Blood2014
25132497BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell2014
25186176A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Sci Transl Med2014
23303510HitWalker: variant prioritization for personalized functional cancer genomics.Bioinformatics2013
  • 1 - 50 of 79

Recommended Authors

Jonathan V Nguyen
Moffitt Cancer Center
Career Start Year 2017
Number of shared co-authors 4
Veronique Litalien
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 1
Kevin H Lin
Duke University
Career Start Year 2014
Number of shared co-authors 1
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 7
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 4
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 2
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Catherine C Smith
University of California San Francisco
Career Start Year 2009
Number of shared co-authors 12
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 9
Elisabeth A Lasater
University of California san francisco
Career Start Year 2008
Number of shared co-authors 1
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 3
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 24
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 10
Oliver Hantschel
Institute of Physiological Chemistry, University of Marburg 35032 Marburg Germany .
Career Start Year 2003
Number of shared co-authors 19
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 5
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 25
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 17
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 6
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 13
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 16
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 14
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 1992
Number of shared co-authors 12
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 45
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 9
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 12
Neil P Shah
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 21
Junia V Melo
University of Adelaide
Career Start Year 1984
Number of shared co-authors 16
Donald Small
Johns Hopkins University School of Medicine
Career Start Year 1977
Number of shared co-authors 7

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 67
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 39
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 33
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 30
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 19
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 18
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 16
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 16
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 15
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 13
Bill H Chang
Oregon Health and Science University
Co-authored papers 11
Matthew S Zabriskie
University of Utah
Co-authored papers 9
Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 9
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 8
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 7
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Co-authored papers 7
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Monika A Davare
Oregon Health Sciences University
Co-authored papers 6
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 6
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 6
Elie Traer
Oregon Health & Science University
Co-authored papers 6
Nicola Long
Oregon Health and Science University
Co-authored papers 6
Jacob P Wagner
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Co-authored papers 5
Richard D Press
Oregon Health and Science University
Co-authored papers 5
Kara Johnson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Anna Reister Schultz
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Angela Rofelty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Release 1.2